Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab during active surveillance after neoadjuvant chemoradiation for esophageal cancer (SANO-3)
2022-000355-37Phase 2Active
- Sponsor
- Erasmus MC Cancer Institute
- Start
- Aug 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, single-arm trial of nivolumab in esophageal cancer and Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Erasmus MC Cancer Institute. Primary endpoint: Disease-free survival. Started Aug 2022; status: active.
02
Drugs
03
Conditions
esophageal cancerEsophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on 2022-000355-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000355-37.